The jury is out on if and/or where nonpoppy- derived opiate-like drugs fit into a self-treated pain armamentarium. Consumers might argue that their opiate options are limited and that they should have a right to use naturally occurring substances, particularly in the current environment of rapid opioid tapers or abrupt cessation due to fear of prescription regulatory oversight, government, and/or third-party payer policies. Some argue that these products should be accessible, while oOthers believe that use should be regulated by the FDA and overseen by a boniafied fide healthcare provider. These products combine with opiate receptors that have predictable pharmacodynamic activities. Unbeknownst to providers, and absent from traditional urine drug screen analyses, use of these products by consumers are increasing for purposes of treating pain, mitigating withdrawal from previously prescribed opioids, and for euphoric effects. They are not derived from the poppy plant but instead from other plants or dairy products. Join us in this exciting debate to hear both sides of the story for use, misuse, abuse, consumer advocacy, and risks to patients and providers. There will be plenty of time for live interaction.